AI summary by TwinMind
The Promise and Peril of Fast-Tracking the Coronavirus Vaccine | WSJ
The Wall Street Journal
8m 15s
Vaccine Development Timeline Crisis
- Coronavirus crisis forcing breakneck pace vaccine development
- Economies cannot reopen safely/permanently without effective vaccine
- Traditional vaccine development: average 10 years (2013 study)
- COVID-19 vaccine target: 12-18 months to market
- Emergency use authorization possible before end of year
Factors Enabling Accelerated Development
- Prior knowledge of coronaviruses (SARS, MERS)
- Improvements in viral genome sequencing
- Advancements in bioengineering technologies
- Unprecedented government support and funding
- Shortened testing timeline through parallel processing
Traditional vs. Accelerated Testing Process
- Traditional sequence: cells → animals (mice → monkeys) → challenge studies → human trials
- Each phase requires safety/effectiveness proof before advancing
- Challenge studies: vaccinate animal, intentionally expose to virus
- Three stages human trials, each testing more people
- FDA approval required for each stage
- Current approach: parallel testing instead of sequential
- Not skipping steps, doing simultaneously
- Costs significantly more, requires more work
Current Development Status
- Novel coronavirus discovered/sequenced <6 months ago
- Phase 1 human trials already started: Inovio, Pfizer
- Moderna started Phase 2
- Others preparing Phase 2 before Phase 1 completion
- Phase 1 trials typically run 1 year, but not waiting full period
- Expediting due to COVID-19 devastation concerns
Vaccine Mechanism and Target
- Vaccines trick body into thinking virus infiltrated
- Immune system produces antibodies/defenses
- Target: spike protein (virus uses to enter cells)
- SARS/MERS showed spike protein = major neutralizing antibody target
- Neutralizing antibodies essential to fight infection
Herd Immunity Concept
- Pandemic ends when sufficient population immunity achieved
- Immunity sources: natural infection or vaccination
- Vaccination = "gentler path" than mass infection
- Largest, most collaborative vaccine development effort in scientists' lifetimes
Four Main Vaccine Strategies
Weakened/Inactivated Virus Vaccines
- Most common type (annual flu shot)
- Most experience with this approach
- Costly, time-consuming mass production
- Not preferred approach for COVID-19
Protein-Based Vaccines
- Carry key virus parts (spike protein) into body
- Developers: Sanofi, GlaxoSmithKline, dozens others
- More diverse proteins with various shapes/characteristics
- Require more development work
Viral Vector Vaccines
- Use inactivated virus stuffed with spike protein genetic code
- Cells produce viral proteins, immune system recognizes
- Johnson & Johnson developing this type
- Uses adenovirus (common cold virus, replication incompetent)
Genetic Code Vaccines
- Contain spike protein instructions
- Developers: Inovio, Pfizer, Moderna
- Never approved for humans before
- Generating excitement due to speed in development/manufacturing
Manufacturing and Safety Concerns
- Pfizer running multiple candidates (US, Germany)
- Ramping manufacturing capacity before knowing effectiveness
- Key requirements: safety, effectiveness, consistency
- Manufacturing changes can introduce unforeseen safety issues
- Historical example: discontinued polio vaccine
- Vaccines given to healthy people, must ensure no organ function impact
Production and Distribution Challenges
- Goal: 1 billion doses by end 2021
- Other companies committing hundreds of millions/billions
- Still insufficient for global population
- Unknown protection durability: 6 months to 2+ years
- If short duration, frequent boosting required
Human Behavior Hurdle
- Final, most important obstacle
- Vaccine acceptance crucial for success
- 50% rejection rate would defeat purpose
- Major problem in US population
